BRCA1 or CDK12 loss sensitizes cells to CHK1 inhibitors

Varování

Publikace nespadá pod Ekonomicko-správní fakultu, ale pod Přírodovědeckou fakultu. Oficiální stránka publikace je na webu muni.cz.
Autoři

PACULOVÁ Hana KRAMARA Juraj ŠIMEČKOVÁ Šárka FEDR Radek SOUČEK Karel HYLSE Ondřej PARUCH Kamil SVOBODA Marek MISTRÍK Martin KOHOUTEK Jiří

Rok publikování 2017
Druh Článek v odborném periodiku
Časopis / Zdroj Tumor Biology
Fakulta / Pracoviště MU

Přírodovědecká fakulta

Citace
www https://doi.org/10.1177/1010428317727479
Doi http://dx.doi.org/10.1177/1010428317727479
Obor Organická chemie
Klíčová slova DNA damage response; BRCA1; CDK12; CHK1 inhibitor; transcription
Popis A broad spectrum of tumors develop resistance to classic chemotherapy, necessitating the discovery of new therapies. One successful strategy exploits the synthetic lethality between poly(ADP-ribose) polymerase 1/2 proteins and DNA damage response genes, including BRCA1, a factor involved in homologous recombination–mediated DNA repair, and CDK12, a transcriptional kinase known to regulate the expression of DDR genes. CHK1 inhibitors have been shown to enhance the anti-cancer effect of DNA-damaging compounds. Since loss of BRCA1 increases replication stress and leads to DNA damage, we tested a hypothesis that CDK12- or BRCA1-depleted cells rely extensively on S-phase-related CHK1 functions for survival. The silencing of BRCA1 or CDK12 sensitized tumor cells to CHK1 inhibitors in vitro and in vivo. BRCA1 downregulation combined with CHK1 inhibition induced excessive amounts of DNA damage, resulting in an inability to complete the S-phase. Therefore, we suggest CHK1 inhibition as a strategy for targeting BRCA1- or CDK12-deficient tumors.
Související projekty:

Používáte starou verzi internetového prohlížeče. Doporučujeme aktualizovat Váš prohlížeč na nejnovější verzi.